AP NEWS
Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Novaremed Presents Top-Line Results from Phase 2a Diabetic Neuropathic Pain Study of NRD.E1 at NeuPSIG 2019

May 17, 2019

BASEL, Switzerland--(BUSINESS WIRE)--May 17, 2019--

Novaremed AG, a clinical-stage Swiss biopharmaceutical company, today announced a poster presentation highlighting the top-line results from a Phase 2a (Proof of Concept) study of NRD.E1 for the treatment of diabetic neuropathic pain (DNP). The poster presentation took place at the 7 th International Congress on Neuropathic Pain Meeting (NeuPSIG) in London, UK on May 9-11, 2019.

“This was our first communication at a leading neuropathic pain-focused event. Novaremed’s lead drug, NRD.E1 is a non-opioid small molecule for the treatment of neuropathic pain. The results of our Phase 2a in patients with DNP showed clinically relevant treatment benefit from NRD.E1 across multiple primary and secondary endpoints, providing a strong scientific foundation for advancing the development of NRD.E1 into the upcoming global Phase 2b study in DNP,” said Sara Mangialaio, Head of R&D and Chief Medical Officer of Novaremed AG. “NRD.E1 has the potential to address a major unmet medical need in DNP.”

Poster Presentation Details:

Presentation Title: Novaremed is developing NRD.E1, an innovative therapy for diabetic neuropathic pain - Results from a proof of concept study
https://www.novaremed.com/wp-content/uploads/2019/05/PS90_Novaremed_NRDE1PoCinDNP_20190503_c.pdf
Presenter: Sara Mangialaio, MD, PhD, Novaremed
Presentation Date: May 11, 2019

Notes to the Editor:

About Novaremed
Novaremed Ltd. was founded in 2008 in Israel and reincorporated as Novaremed AG in Switzerland late 2017. Novaremed is developing NRD.E1, an orally-active small molecule with a differentiated mechanism of action for the treatment of Diabetic Neuropathic Pain (DPN). In a Phase 2a Proof of Concept study, NRD.E1 showed clinically relevant reduction in patient reported pain. Novaremed is currently preparing for a global Phase 2b study in DPN, expected to start in Q4 2019. For more information, visit www.novaremed.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190517005176/en/

CONTACT: Subhasis Roy

Chief Operating Officer

Tel: +41 79 2075715

Email:subhasis.roy@novaremed.com

KEYWORD: EUROPE SWITZERLAND

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL RESEARCH DIABETES SCIENCE

SOURCE: Novaremed

Copyright Business Wire 2019.

PUB: 05/17/2019 06:13 AM/DISC: 05/17/2019 06:13 AM

http://www.businesswire.com/news/home/20190517005176/en

All contents © copyright 2019 The Associated Press. All rights reserved.